Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit